BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

TScan, Novartis partner to develop TCR therapies  TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research...
BioCentury | Apr 10, 2020
Deals

Amid flurry of COVID-19 deals, Vir turns to Samsung to ramp up manufacturing

While its two SARS-CoV-2 antibodies are still months away from entering the clinic, Vir has wasted no time securing manufacturing capacity. The biotech Friday partnered with Samsung Biologics, marking its fourth manufacturing deal. Vir Biotechnology...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

Medicines Co. mum on Novartis takeout rumor  The Medicines Co. (NASDAQ:MDCO) declined to comment to BioCentury on a Bloomberg report that said Novartis AG (NYSE:NVS; SIX:NOVN) is among several companies exploring an acquisition of the...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BC Extra | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
BioCentury | Aug 16, 2019
Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade. On February 22, 2019, China’s National...
BC Extra | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...
BC Week In Review | Mar 22, 2019
Company News

Reports: prosecutors investigate Korea Exchange for Samsung BioLogics IPO

South Korean prosecutors raided Korean Stock Exchange offices after suspecting the exchange eased regulations to allow Samsung BioLogics' 2016 IPO, according to reports. In November, Korea’s Securities and Futures Commission (SFC) temporarily suspended trading of...
Items per page:
1 - 10 of 149